Oramed Pharmaceuticals Return on Equity

Oramed Pharmaceuticals (ORMP) currently reports a ROE of 58.63%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Oramed Pharmaceuticals's ROE history and peer comparisons.

Oramed Pharmaceuticals's ROE of 58.63% is higher than the Healthcare sector average of 22.01%. That is roughly 166.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Oramed Pharmaceuticals's current 58.63% should be judged against Healthcare norms (sector average: 22.01%) and against ORMP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 58.63%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Oramed Pharmaceuticals, and consider following ORMP for alerts when major investors trade the stock.

Oramed Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 58.63% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ORMP with unrelated industries.